0933 ET - AbbVie reports 2Q results ahead of expectations, JPMorgan analysts say in a research note. The top-line beat was fairly broad based, with Both Skyrizi and Rinvoq modestly ahead of estimates. "On the call, we will be closely listening for any updated expectations on 1) uptake of Skyrizi/Rinvoq (and updated guidance for both) and 2) business development commentary," the analysts say. AbbVie is off 1% in early trading, after lowering its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics.